Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

NCT00675870 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Promyelocytic Leukemia

Interventions

DRUG: NRX 195183 Soft Gelatin Capsule

Sponsor

NuRx Pharmaceuticals, Inc.